Regression of Internal Melanoma Metastases Following Application of Topical Imiquimod to Overlying Skin

March 2011 | Volume 10 | Issue 3 | Case Reports | 302 | Copyright © March 2011


Anne K. Miller BS, Reginald Dusing MD, Aaron Meggison MD, Daniel Aires MD

University of Kansas School of Medicine, Departments of Dermatology and Radiology, Kansas City, KS

  1. Balch C, Buzaid A, Soong S, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol.2001;19(16):3635–3648.
  2. SkinCancerNet. Who is most at risk for melanoma. Available at: http://www.skincarephysicians.com/skincancernet/who_is_most.html. Accessed December 21 2009.
  3. Greene MH. The genetics of hereditary melanoma and nevi. 1998 Update. Cancer. 1999;86(11):2464–2477.
  4. Kalialis LV, Drzewiecki KT, Mohammadi M, et al. Spontaneous regression of metastases from malignant melanoma: Case report. Melanoma Res. 2008;18(4):279-283.
  5. Bajetta E, Del Vecchio M, Bernard-Marty C, et al. Metastatic melanoma: Chemotherapy. Semin Oncol. 2009;29(5):427-445.
  6. Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer. 2010;46(2):270-283.
  7. Heber G, Helbil D, Ponitzsch I, et al. Complete remission of cutaneous or subcutaneous melanoma metastases of the scalp with imiquimod therapy. J Dtsch Dermatol Ges. 2009;7(6):534-536.
  8. Mahoney MH, Joseph MG, Temple C. Topical imiquimod therapy for lentigo melanoma. Ann Plast Surg. 2008;61(4):419-424.
  9. Aldara: Package insert. Bristol, NJ Graceway Pharmaceuticals. 2009.

Address for Correspondence

Anne K. Miller, BS3838 Rainbow Blvd, Apt 1402Kansas City, KS 66103Phone: 316-253-9928amiller@kumc.edu
Close Menu